Your browser doesn't support javascript.
loading
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Schiller, Hilmar; Huth, Felix; Schuhler, Carole; Drollmann, Anton; Kaul, Martin; Woessner, Ralph; Shah, Bharti; Weis, Wendy; End, Peter.
Affiliation
  • Schiller H; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Huth F; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Schuhler C; GCE Solutions, Basel, Switzerland.
  • Drollmann A; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Kaul M; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Woessner R; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Shah B; Novartis Institutes for BioMedical Research, East Hanover, NJ, USA.
  • Weis W; Novartis Institutes for BioMedical Research, East Hanover, NJ, USA.
  • End P; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Eur J Pharm Sci ; 172: 106155, 2022 May 01.
Article in En | MEDLINE | ID: mdl-35247543
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Kinase Inhibitors / Neoplasm Proteins Limits: Humans Language: En Journal: Eur J Pharm Sci Journal subject: FARMACIA / FARMACOLOGIA / QUIMICA Year: 2022 Document type: Article Affiliation country: Switzerland Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Kinase Inhibitors / Neoplasm Proteins Limits: Humans Language: En Journal: Eur J Pharm Sci Journal subject: FARMACIA / FARMACOLOGIA / QUIMICA Year: 2022 Document type: Article Affiliation country: Switzerland Country of publication: Netherlands